Group 1 - The core announcement is about the leadership changes at Dongyao Pharmaceutical-B (01875.HK), effective from October 11, 2025 [1] - Fu Shan will transition from a non-executive director to an executive director, overseeing the management and development of the group while continuing as chairman and chair of the nomination and strategic and ESG committees [1] - Liu Jun has resigned from his positions as executive director, CEO, chief scientific officer, and member of the strategic and ESG committees due to personal reasons [1] - Huang Chunying has also resigned from her roles as non-executive director, vice-chairman, and member of the strategic and ESG committees, citing personal reasons [1] - Following Liu Jun's departure, Fu Shan has been appointed as the company's authorized representative in accordance with Listing Rule 3.05, effective from October 11, 2025 [1]
东曜药业-B(01875.HK)：付山调任为执行董事